37.91
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
What analysts say about Revolution Medicines Inc. stockSuperior stock selection - PrintWeekIndia
Revolution Medicines, Iambic Therapeutics Partner to Use AI for Novel RAS-Addicted Cancer Drug Discovery - Insider Monkey
What drives Revolution Medicines Inc. Equity Warrant stock priceTriple returns potential - Autocar Professional
What analysts say about Revolution Medicines Inc. Equity Warrant stockFastest-growing stock picks - PrintWeekIndia
Revolution Medicines publishes research on RAS G12D inhibitor - Investing.com
Revolution Medicines Inc. Equity Warrant Stock Analysis and ForecastHigh-octane financial growth - Autocar Professional
What drives Revolution Medicines Inc. stock priceBreakthrough stock performance - Autocar Professional
Is Revolution Medicines Inc. a good long term investmentMarket-leading capital gains - Autocar Professional
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewswire
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewswire
Revolution Medicines Inc. Stock Analysis and ForecastConsistent wealth multiplication - jammulinksnews.com
Castle Bio, Revolution Medicines get FDA breakthrough statuses - Seeking Alpha
FDA grants breakthrough therapy designation to Revolution Medicines’ lung cancer drug - Investing.com Canada
How will RVMD's EPS trend in Q1 2025? - AInvest
Is Revolution Medicines Inc. Equity Warrant a good long term investmentConsistent high-performance stocks - jammulinksnews.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):